Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Omnicom Group Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Omnicom Group Inc. trades at $78.65 (market cap $21.53B). The key difference: Omnicom Group Inc. is far larger — about 22.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Omnicom Group Inc. pays a 4.08% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Omnicom Group Inc. for 64 Days on average.
| MRVI | OMC | |
|---|---|---|
Market Cap | $972.90M | $21.53B |
Volume | 4,325,710 | 2,515,610 |
Sector | Health | Media |
52-Week High | $9.00 | $88.94 |
52-Week Low | $2.83 | $67.27 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $1.08B | $29.61B |
Dividend Yield | — | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Omnicom Group (OMC) trades at $78.41, up 1.74% with a bullish technical signal despite mixed earnings results. The company shows strong revenue growth to $17.27B in 2025 but reported a net loss of -$54.50M. Analyst consensus is mixed with 32% buy ratings and a $100.50 price target, while recent news highlights leadership in digital marketing and $3.3B in new H1 2026 billings.
OMC presents a value opportunity with attractive P/S of 0.88 and dividend yield, though high P/E of 212.14 reflects earnings volatility. Key risks include advertising market weakness and elevated debt levels, while AI capabilities and post-Interpublic synergies offer growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
